Health ❯ Healthcare ❯ Clinical Research

Drug Development

Clinical Trials Eli Lilly Phase 2 Trials Regulatory Approval Lecanemab Phase 3 Trials Immunotherapy Trials Alzheimer's Treatments Antibody-Drug Conjugates (ADCs) GSK Innovations

3 ARTICLES

last mo.

Sanofi Stops MOBILIZE Phase 3 Trial of Riliprubart in CIDP After Futility Finding

An independent data monitoring committee concluded the study was unlikely to show sufficient efficacy, a result that will shape whether Sanofi advances other riliprubart trials.

3 ARTICLES

2mo ago

Design Therapeutics Reports Early DT-216P2 Data in Friedreich’s Ataxia

5 ARTICLES

3mo ago

Revolution Medicines’ Pancreatic Cancer Drug Lands ASCO Plenary After Phase 3 Survival Gain

3 ARTICLES

6mo ago

Alzheimer’s Study Finds Memory “Replay” Persists but Loses Structure

6 ARTICLES

6mo ago

Vulcan Value Partners' Q4 Letter Reports Gains, Deep Discounts and Portfolio Changes

3 ARTICLES

6mo ago

Monte Rosa’s MRT-8102 Shows Strong Phase 1 Biomarker Effects, Lifting Shares to 52-Week High

3 ARTICLES

7mo ago

Lilly’s Triple-Agonist Retatrutid Delivers About 29% Weight Loss in Phase 3, with Notable Side Effects

8 ARTICLES

8mo ago

Eli Lilly Becomes First Health Care Company Valued at $1 Trillion

4 ARTICLES

9mo ago

Alector Ends Latozinemab After Phase 3 Failure, Slashes Workforce

4 ARTICLES

11mo ago

Rapport Seizure Drug Posts Strong Phase 2 Signal as Company Plans Phase 3

5 ARTICLES

11mo ago

Monthly Oral PrEP Candidate MK-8527 Shows Early Promise in Merck Study

5 ARTICLES

11mo ago

Stanford Spray-Drying Method Could Turn Many IV Biologics Into Quick Injections

4 ARTICLES

11mo ago

MHRA Licenses Teplizumab to Delay Onset of Type 1 Diabetes

6 ARTICLES

11mo ago

FDA Approves Vizz Eye Drops for Presbyopia

3 ARTICLES

last yr.

EMA Committee Recommends EU Approval for First Oral Postpartum Depression Treatment

3 ARTICLES

last yr.

Antibiotic Energy Drain Found to Accelerate Bacterial Resistance

7 ARTICLES

last yr.

Eli Lilly’s Lepodisiran Achieves 94% Reduction in Genetic Heart Disease Risk Factor in Phase 2 Trial

Drug Development

Sanofi Stops MOBILIZE Phase 3 Trial of Riliprubart in CIDP After Futility Finding

Design Therapeutics Reports Early DT-216P2 Data in Friedreich’s Ataxia

Revolution Medicines’ Pancreatic Cancer Drug Lands ASCO Plenary After Phase 3 Survival Gain

Alzheimer’s Study Finds Memory “Replay” Persists but Loses Structure

Vulcan Value Partners' Q4 Letter Reports Gains, Deep Discounts and Portfolio Changes

Study Finds Blood Test Predicts Tarlatamab Benefit in Small Cell Lung Cancer

Brazil Authorizes Leqembi for Early-Stage Alzheimer’s Treatment

Splice-Switching ASO Collapses Oncogenic Circuit in Pancreatic Cancer Models

Monte Rosa’s MRT-8102 Shows Strong Phase 1 Biomarker Effects, Lifting Shares to 52-Week High

Lilly’s Triple-Agonist Retatrutid Delivers About 29% Weight Loss in Phase 3, with Notable Side Effects

Never miss stories about

Drug Development

Eli Lilly Becomes First Health Care Company Valued at $1 Trillion

Alector Ends Latozinemab After Phase 3 Failure, Slashes Workforce

Rapport Seizure Drug Posts Strong Phase 2 Signal as Company Plans Phase 3

Monthly Oral PrEP Candidate MK-8527 Shows Early Promise in Merck Study

Stanford Spray-Drying Method Could Turn Many IV Biologics Into Quick Injections

MHRA Licenses Teplizumab to Delay Onset of Type 1 Diabetes

FDA Approves Vizz Eye Drops for Presbyopia

EMA Committee Recommends EU Approval for First Oral Postpartum Depression Treatment

Antibiotic Energy Drain Found to Accelerate Bacterial Resistance

Eli Lilly’s Lepodisiran Achieves 94% Reduction in Genetic Heart Disease Risk Factor in Phase 2 Trial

Never miss stories about

Drug Development